Isofol Medical AB (publ)
SSE:ISOFOL.ST
0.62 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Isofol Medical AB (publ) |
Symbool | ISOFOL.ST |
Munteenheid | SEK |
Prijs | 0.616 |
Beurswaarde | 99,493,240 |
Dividendpercentage | 0% |
52-weken bereik | 0.45 - 1.24 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Roger Tell M.D., Ph.D. |
Website | https://isofolmedical.com |
An error occurred while fetching data.
Over Isofol Medical AB (publ)
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)